AROA BIOSURGERY LIMITED — Director's Dealing 2024

Aug 22, 2024

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Aroa Biosurgery Limited ARBN 638 867 473

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Brian Ward
Date of last notice	31 March 2023

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect	Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	N/A
Date of change	22 August 2024
No. of securities held prior to change		IndirectMr Brian Ward & Mrs Tracey Ward<Arawai No 2 A/C>33,125,800Fully Paid OrdinaryShares3,132,525Options exercisableat $0.75 expiring 23July 2025591,768Optionsexercisableat $Nil expiring 13November 2027649,695Options exercisableat $1.165 expiring on13 November 2027254,972Options exercisableat $1.165 expiring 29February 2028453,206Options exercisableat $Nilexpiring 29 February2028

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Class	Performance Rights	Performance Rights
Number acquired	961,255
Number disposed	-
Value/Consideration	Nil
Note: If consideration is non-cash, provide details and estimated valuation
No. of securities held after change	Indirect
	Mr Brian Ward & Mrs Tracey Ward <Arawai
	No 2 A/C>
	33,125,800	Fully Paid Ordinary Shares
	3,132,525	Options exercisable at
		$0.75 expiring 23 July 2025
	1,217,610	Options exercisable at $Nil
		expiring 13 November 2027
	649,695	Options exercisable at
		$1.165 expiring on 13
		November 2027
	254,972	Options exercisable at
		$1.165 expiring 29
		February 2028
	453,206	Options exercisable at $Nil
		expiring 29 February 2028
	961,255	Performance Rights
		expiring1 August 2027
Nature of change	Issued on	22 August 2024 pursuant to
Example: on-market trade, off-market trade, exercise of options, issue ofsecurities under dividend reinvestment plan, participation in buy-back	shareholder approval received at the AnnualGeneral Meeting held on 23 July 2024.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	-
Nature of interest	-
Name of registered holder	-
(if issued securities)
Date of change	-
No. and class of securities to which interest	-
related prior to change
Note: Details are only required for a contract in relation to which the interest
has changed
Interest acquired	-
Interest disposed	-
Value/Consideration	-
Note: If consideration is non-cash, provide details and an estimated
valuation
Interest after change	-

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 3 –[+] Closed period

Were the interests in the securities or contracts No detailed above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to N/A allow the trade to proceed during this period? If prior written clearance was provided, on what N/A date was this provided?

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3